Completed PHASE3 INTERVENTIONAL 2-arm NCT00544232

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF ± Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage ± Darbepoetin Alfa in Patients With Primary Breast Cancer

Sponsor: Amgen

Conditions Breast Cancer

Interventions Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa

Updated 6 times since 2017 Last updated: Feb 12, 2016 Started: Aug 31, 2002 Primary completion: Sep 30, 2006 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00544232, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Amgen, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Apr 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Bristol-Myers Squibb
GBG Forschungs GmbH
Pharmacia

Data source: GBG Forschungs GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.